Single-agent and combination chemotherapy with etoposide in the acute leukemias of childhood.

[1]  Bowman Wp.  Childhood acute lymphocytic leukemia: progress and problems in treatment. , 1981, Canadian Medical Association journal.

[2]  R. Aur,et al.  VM‐26 and cytosine arabinoside combination chemotherapy for initial induction failures in childhood lymphocytic leukemia , 1980, Cancer.

[3]  R. Aur,et al.  Combined VM‐26 and cytosine arabinoside in treatment of refractory childhood lymphocytic leukemia , 1980, Cancer.

[4]  D. Hammond,et al.  Phase II study of VP-16-213 in childhood malignant disease: a Children's Cancer Study Group Report. , 1979, Cancer treatment reports.

[5]  R. Aur,et al.  Recurrent childhood lymphocytic leukemia. Clinical and cytokinetic studies of cytosine arabinoside and methotrexate for maintenance of second hematologic remission , 1978, Cancer.

[6]  B. Hoogstraten,et al.  5‐azacytidine in acute leukemia , 1978, Cancer.

[7]  D. V. Von Hoff,et al.  VM 26 and VP 16–213: A comparative analysis , 1977, Cancer.

[8]  B. Barlogie,et al.  Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16-213. , 1976, Cancer treatment reports.

[9]  I. Smith,et al.  VP 16-213 in acute myelogenous leukaemia , 1976, Postgraduate medical journal.

[10]  P. Creaven,et al.  Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotixin glucopyranoside derivatives. , 1975, European journal of cancer.

[11]  D. Roberts,et al.  Response of L1210 to combinations of cytosine arabinoside and VM-26 or VP16-213. , 1975, European journal of cancer.

[12]  T. Avery,et al.  4'-demethylepipodophyllotoxin 9-(4,6-o-2-thenylidene-beta-D-glucopyranoside) (NSC-122819; VM-26) and 4'-demethylepipodophyllotoxin 9-(4.6-0-ethylidene-beta-D-glucopyranoside) (NSC-141540; VP-16-213) in childhood cancer: preliminary observations. , 1975, Cancer chemotherapy reports.

[13]  K. Brunner,et al.  [Initial results with a epipodophyllotoxin derivative VP 16-213 in the treatment of acute leukemia]. , 1975, Schweizerische medizinische Wochenschrift.

[14]  J. Misset,et al.  Two epipodophyllotoxin derivatives, VM 26 and VP 16213, in the treatment of leukemias, hematosarcomas, and lymphomas , 1974, Cancer.

[15]  H. Stähelin.  4'-Demethyl-epipodophyllotoxin thenylidene glucoside (VM 26), a podophyllum compound with a new mechanism of action. , 1970, European journal of cancer.